Abstract

In recent years, the number of useful chemical biology information of protein-protein interactions in the HIV life cycle and related inhibitors, is growing rapidly, which makes protein-protein interactions a new investigative area for antiviral drug intervention. This review will summarize recent work in this field, mainly focusing on the utilization of small molecules targeted against a variety of protein-protein interactions that have great therapeutic feasibility for HIV infection, and lastly outline some other important protein-protein interactions with a potential to advance into novel anti- HIV drug targets in future.

Keywords: HIV, AIDS, drug design, drug targets, protein-protein interactions, inhibitor, Anti-HIV, anti-AIDS, reverse transcriptase, protease, integrase, CCR5 coreceptor, HAART), capsid protein, NF-B, Rev protein, RNase H, TEFb, allosteric site, GP120, –, CD4, (ELISA), Schiffs base linkage, Bris-tol-Myers Squibb, clinical trials, HIV-1 inhibition, MAPPIT, HIV enzymes, Dimerization Inhibitors, HIV therapy, peptidomimetics, PR dimerization inhibitors, SAR, VIF-APOBEC3G, LEDGF/p75, CHIBA-3003, SQs, cell-based assays, (Vpr), Gag, GAG-TSG101, CRM1-NES